Description
Merit Medical Acquires Solo Pace for $45 Million — A Pivotal Move Into Structural Heart!
Merit Medical Systems Inc. reported third-quarter 2026 total revenue of $416 million, marking an 8% year-over-year increase on both GAAP and constant currency bases, exceeding prior expectations. Organic constant currency growth was robust at 9%, driven by strong demand in the U.S. (up 11%) and moderate growth internationally (up 3%). This growth was fairly balanced across its foundational product category (8% organic growth) and therapeutic product category (11% organic growth), supported by vascular intervention, oncology, endoscopy, and cardiac therapies platforms. Profitability improved notably despite a slight decline in gross margin to 52.8%, influenced by manufacturing variances and higher freight costs. Non-GAAP operating margin increased by 160 basis points to 21.3%, and non-GAAP EPS rose 22% to $1.12, both surpassing guidance. Free cash flow generation was solid at nearly $53 million. Operating expenses showed only a modest increase, reflecting disciplined cost management with operating income up 17% to $88.5 million.



